Draft of clinical guidelines for the diagnosis and treatment of differentiated thyroid cancer in adult patients
暂无分享,去创建一个
S. A. Ivanov | A. Guz | S. Podvyaznikov | I. Reshetov | A. Mudunov | G. Melnichenko | R. Chernikov | E. Kostromina | T. Semiglazova | D. G. Beltsevich | V. Vanushko | I. S. Romanov | I. Sleptsov | E. Choinzonov | P. Rumyantsev | A. Nevolskikh | S. Ivanov | D. Kulbakin | I. Gulidov | M. Kropotov | S. Musin | A. Polyakov | A. Gevorkov | N. Rubtsova | N. Falaleeva | A. Ilyin | V. Krylov | A. Shurinov | E. Borodavina | P. Isaev | L. Vladimirova | A. V. Ignatova | V. Polkin | N. Severskaya | Y. Alymov | E. Khmelevsky | A. Stepanova | S. Kutukova | A. N. Rudyk | Z. Radjabova | T. A. Aghababyan
[1] R. Chernikov,et al. Targeted therapy of anaplastic thyroid cancer , 2023, Head and Neck Tumors (HNT).
[2] A. Gianoukakis,et al. A randomized study to evaluate the safety and efficacy of two dosages of lenvatinib – 18 and 24 mg – in patients with radioiodrefract differentiated thyroid cancer , 2022, Head and Neck Tumors (HNT).
[3] J. Soria,et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] V. Krylov,et al. Radioiodine Ablation for Thyroid Cancer. Historical and Modern Aspects. Literature Review , 2021, Journal of oncology: diagnostic radiology and radiotherapy.
[5] M. Kerin,et al. Radioiodine Remnant Ablation for Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis. , 2021, JAMA otolaryngology-- head & neck surgery.
[6] Frederick D. Grant,et al. A JOINT STATEMENT FROM THE AMERICAN THYROID ASSOCIATION. , 2021, Thyroid : official journal of the American Thyroid Association.
[7] T. Giordano,et al. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. , 2021, Thyroid : official journal of the American Thyroid Association.
[8] A. A. Semenov,et al. TREATMENT OF BRAFV600E POSITIVE ANAPLASTIC THYROID CARCINOMA: CASE REPORT , 2020 .
[9] M. Beheshti,et al. Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain , 2020, Journal of clinical medicine.
[10] Mark Robson,et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] L. Jia,et al. Zoledronic acid inhibits thyroid cancer stemness and metastasis by repressing M2-like tumor-associated macrophages induced Wnt/β-catenin pathway. , 2020, Life sciences.
[12] K. Bible,et al. Bone metastases in thyroid cancer , 2020, Journal of bone oncology.
[13] M. Papotti,et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] M. Luster,et al. Management Guidelines for Children With Thyroid Nodules and Differentiated Thyroid Cancer , 2018, Pediatrics.
[15] F. Vaisman,et al. The Impact of Zoledronic Acid and Radioactive Iodine Therapy on Morbi-Mortality of Patients with Bone Metastases of Thyroid Cancer Derived from Follicular Cells , 2018, European Thyroid Journal.
[16] M. Brose,et al. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial , 2018, Head and neck tumors (HNT).
[17] W. Knoefel,et al. Measurement of Basal Serum Calcitonin for the Diagnosis of Medullary Thyroid Cancer , 2017, Hormone and Metabolic Research.
[18] E. Cibas,et al. The 2017 Bethesda System for Reporting Thyroid Cytopathology. , 2017, Journal of the American Society of Cytopathology.
[19] P. Trimboli,et al. Measurement of thyroglobulin, calcitonin, and PTH in FNA washout fluids , 2017, Clinical chemistry and laboratory medicine.
[20] J. Utikal,et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] K. Hess,et al. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. , 2017, Thyroid : official journal of the American Thyroid Association.
[22] J. Won,et al. Recurrence and Survival After Gross Total Removal of Resectable Undifferentiated or Poorly Differentiated Thyroid Carcinoma. , 2016, Thyroid.
[23] C. Reiners,et al. Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[24] T. Jacks,et al. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer , 2014, Proceedings of the National Academy of Sciences.
[25] E. Alexander,et al. The importance, and important limitations, of ultrasound imaging for evaluating thyroid nodules. , 2013, JAMA internal medicine.
[26] M. Friedrich-Rust,et al. Interobserver Agreement of Thyroid Imaging Reporting and Data System (TIRADS) and Strain Elastography for the Assessment of Thyroid Nodules , 2013, PloS one.
[27] D. Loeb,et al. Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP , 2013, Clinical & experimental pharmacology.
[28] A. Gawande,et al. Thyroid nodule size and prediction of cancer. , 2013, The Journal of clinical endocrinology and metabolism.
[29] E. Ding,et al. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. , 2012, The Journal of clinical endocrinology and metabolism.
[30] J. Copland,et al. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).
[31] B. Biondi,et al. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. , 2010, Thyroid : official journal of the American Thyroid Association.
[32] Jack Yang,et al. Fine‐needle aspiration of thyroid nodules: A study of 4703 patients with histologic and clinical correlations , 2007, Cancer.
[33] Gerard M Doherty,et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.
[34] R. Golouh,et al. Effect of primary treatment on survival in anaplastic thyroid carcinoma. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[35] S. Sherman,et al. Prognosis and treatment of brain metastases in thyroid carcinoma. , 1997, The Journal of clinical endocrinology and metabolism.
[36] T. Uruno,et al. Thyroid Lobectomy for Papillary Thyroid Cancer: Long-term Follow-up Study of 1,088 Cases , 2013, World Journal of Surgery.
[37] A. Pontecorvi,et al. Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules. , 1998, Thyroid : official journal of the American Thyroid Association.